Pediatric hereditary angioedema due to C1-inhibitor deficiency
Open Access
- 28 July 2010
- journal article
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 6 (1) , 18
Abstract
Hereditary angioedema (HAE) resulting from the deficiency of the C1 inhibitor (C1-INH) is a rare, life-threatening disorder. It is characterized by attacks of angioedema involving the skin and/or the mucosa of the upper airways, as well as the intestinal mucosa. In approximately 50 per cent of cases, clinical manifestations may appear during childhood. The complex management of HAE in pediatric patients is in many respects different from the management of adults. Establishing the diagnosis early, preferably before the onset of clinical symptoms, is essential in cases with a positive family history. Complement studies usually afford accurate diagnosis, whereas molecular genetics tests may prove helpful in uncertain cases. Appropriate therapy, supported by counselling, suitable modification of lifestyle, and avoidance of triggering factors (which primarily include mechanical trauma, mental stress and airway infections in children) may spare the patient unnecessary surgery and may prevent mortality. Prompt control of edematous attacks, short-term prophylaxis and intermittent therapy are recommended as the primary means for the management of pediatric cases. Medicinal products currently used for the treatment of children with hereditary angioedema include antifibrinolytics, attenuated androgens, and C1-INH replacement therapy. Current guidelines favour antifibrinolytics for long-term prophylaxis because of their favorable safety profile but efficacy may be lacking. Attenuated androgens administered in the lowest effective dose are another option. C1-INH replacement therapy is also an effective and safe agent for children. Regular monitoring and follow-up of patients are necessary.Keywords
This publication has 63 references indexed in Scilit:
- C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progressTrends in Molecular Medicine, 2009
- Treatment of skin swellings with C1‐inhibitor concentrate in patients with hereditary angio‐oedemaAllergy, 2008
- Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new?Annals of Allergy, Asthma & Immunology, 2008
- Established and new treatments for hereditary angioedema: An updateMolecular Immunology, 2007
- Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyondJournal of Allergy and Clinical Immunology, 2004
- Oxandrolone treatment of childhood hereditary angioedemaAnnals of Allergy, Asthma & Immunology, 2004
- The Hungarian HAE experienceTransfusion and Apheresis Science, 2003
- Eradication of Helicobacter pylori and improvement of hereditary angioneurotic oedemaThe Lancet, 2001
- Angiotensin converting enzyme inhibitor-induced angioedema: a report of two casesPediatric Nephrology, 1999
- In-Vivo-Aktivierung der vierten Komponente des Komplementsystems (C4) bei Früh- und Reifgeborenen mit generalisierten bakteriellen InfektionenKlinische Padiatrie, 1990